Table 2.
Estimated 14-week risks of symptomatic, asymptomatic, and any COVID-19 diagnosis by treatment group, EPICOS randomized trial
| Symptomatic COVID-19 | Cases/n | 14-week risk % (95% CI) |
Risk difference % (95% CI) |
Risk ratio (95% CI) |
|---|---|---|---|---|
| TDF/FTC + HCQ | 3/220 | 1.10 (0.00–2.55) | -1.70 (-4.41–1.09) | 0.39 (0.00–1.98) |
| TDF/FTC | 3/233 | 0.94 (0.00–2.63) | -1.85 (-4.43–1.16) | 0.34 (0.00–2.06) |
| HCQ | 3/231 | 1.37 (0.00–3.12) | -1.42 (-4.48–1.34) | 0.49 (0.00–2.29) |
| Placebo | 5/223 | 2.79 (0.60–5.22) | Reference | Reference |
| Asymptomatic COVID-19 | ||||
| TDF/FTC + HCQ | 10/220 | 5.51 (2.25–9.04) | -4.61 (-10.4–1.30) | 0.54 (0.21–1.19) |
| TDF/FTC | 17/233 | 8.44 (4.70–12.6) | -1.68 (-7.72–4.26) | 0.83 (0.45–1.66) |
| HCQ | 18/231 | 9.01 (5.37–13.3) | -1.11 (-7.06–5.16) | 0.89 (0.49–1.91) |
| Placebo | 18/223 | 10.1 (5.49–14.5) | Reference | Reference |
| Any COVID-19 | ||||
| TDF/FTC + HCQ | 13/220 | 6.56 (2.75–10.27) | -6.17 (-12.32–0.01) | 0.51 (0.21–1.00) |
| TDF/FTC | 20/233 | 9.31 (5.79–13.69) | -3.42 (-9.61–3.32) | 0.81 (0.44–1.49) |
| HCQ | 21/231 | 10.35 (6.23–14.82) | -2.39 (-8.80–4.28) | 0.73 (0.41–1.38) |
| Placebo | 23/223 | 12.74 (7.92–17.44) | Reference | Reference |
HCQ, hydroxychloroquine; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate.